Zura Bio (ZURA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ZURA Zura Bio

Watchlist

4.920
+0.030+0.61%

Close Oct 18 16:00 ET

4.800
-0.120-2.44%

Post 20:01 ET

313.77MMarket Cap-11207P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Companies Like Zura Bio (NASDAQ:ZURA) Are In A Position To Invest In Growth
Simply Wall StOct 18 11:58 ET
Bullish Zura Bio Insiders Loaded Up On US$1.01m Of Stock
Yahoo FinanceOct 17 10:26 ET
Zura Bio Management to Meet With Cantor Fitzgerald
TipRanksOct 16 08:11 ET
Athanor Capital, LP Adjusts Stake in Zura Bio Ltd
Yahoo FinanceSep 23 15:05 ET
Institutions Profited After Zura Bio Limited's (NASDAQ:ZURA) Market Cap Rose US$45m Last Week but Private Equity Firms Profited the Most
Yahoo FinanceSep 20 09:27 ET
Zura Bio Is Maintained at Overweight by Piper Sandler
Dow JonesSep 19 12:40 ET · Ratings

Comments

Methodman10

Oct 17 14:32

$Zura Bio (ZURA.US)$ big move ahead. daily chart looks great

Trytosaveabit

Jun 14 05:04

Update

$Zura Bio (ZURA.US)$ Zura Bio Ltd: Tibulizumab (Zb-106) Was Well Tolerated and Neutralized Il-17a and Baff in a Phase 1 Study in Patients With Sjogren's Syndrome! Presents data at EULAR 2024

Drosen21

Jun 12 08:09

Hedgies may be confused over at Cantor…

$Zura Bio (ZURA.US)$ One is overweight and another to buy 🤫

Jaguar8

Jun 3 06:31

NEWS

$Zura Bio (ZURA.US)$
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...

Stock Region

May 6 05:44

Biotechnology Company Receives ''Overweight'' Rating From Investment Firm: 462% Upside

Zura Bio Garners Enthusiastic Ratings from Analysts with a Bright Outlook.
Zura Bio (NASDAQ:ZURA), Piper Sandler, a prestigious investment firm, has initiated coverage on the biotechnology company, assigning it an "overweight" rating and setting an ambitious price target of $26. This optimistic forecast suggests a potential upside of 462.77% from the stock's previous close. The announcement by Piper Sandler und...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

ZURA Zura Bio

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target